VULVAR CANCER

This study aims to improve treatment for vulvar cancer by personalizing surgery based on the tumor's characteristics. Researchers will test whether adjusting surgical margins based on whether the cancer is linked to HPV infection or a p53 mutation leads to better outcomes and few…

This study is observing how well the drug T-DXd works for people with advanced HER2-positive cancers who have already tried other treatments and have no good options left. It will follow about 100 patients in real-world US clinics to see how their tumors respond and how long the …

This study is testing the safety and effectiveness of a new investigational drug called GI-101 for people with advanced or metastatic solid tumors. The drug is designed to work in two ways to help the immune system fight cancer. Researchers will test it alone and in combination w…

This study is testing whether the oral drug belzutifan can help control recurrent clear cell cancers of the ovary, uterus, cervix, and other gynecologic sites. It will enroll 32 adults who have already received platinum-based chemotherapy. Researchers will measure how well the dr…

This study is testing whether using MRI scans instead of CT scans to guide radiation therapy for gynecologic cancers can reduce side effects and improve treatment accuracy. Researchers at Johns Hopkins will compare how well MRI helps doctors target tumors while sparing healthy or…

This study is testing a new personalized treatment for advanced cancers caused by HPV. Doctors take a patient's own immune cells, modify them in a lab to better target the cancer, and infuse them back to try to shrink tumors before standard therapy like chemo or surgery. The goal…

This study is testing a treatment called electrochemotherapy for women whose vulvar cancer has come back. The treatment combines a cancer drug with electric pulses to help the drug get into the tumor cells more effectively. The main goal is to shrink the tumors enough to avoid or…

This study aims to see if tracking changes in a common inflammation marker (CRP) in the blood can predict how well patients with advanced gynecologic cancers respond to immunotherapy. It will involve 120 women already scheduled to receive standard immunotherapy and chemotherapy. …

This study aims to see if changes in what people buy—like pain relief or digestive aids—can serve as an early warning sign for certain cancers. Researchers will compare the shopping history of 1,450 recently diagnosed cancer patients with 1,450 people without cancer, using up to …